

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Nicholas V. Perricone	03/27/2007
RECEIVING PARTY DATA	
Name:	Transdermal Biotechnology, Inc.
Street Address:	639 Research Parkway
City:	Meriden
State/Country:	CONNECTICUT
Postal Code:	06450
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	13024689
CORRESPONDENCE DATA	
Fax Number:	(203)327-1096
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	203-324-6155
Email:	ccobb@ssjr.com
Correspondent Name:	Stephen P. McNamara
Address Line 1:	986 Bedford Street
Address Line 2:	St. Onge Steward Johnston & Reens
Address Line 4:	Stamford, CONNECTICUT 06905
ATTORNEY DOCKET NUMBER:	01961-P0210D
NAME OF SUBMITTER:	Stephen P. McNamara
Total Attachments: 3 source=Assignment to Transdermal Biotechnology, Inc#page1.tif source=Assignment to Transdermal Biotechnology, Inc#page2.tif source=Assignment to Transdermal Biotechnology, Inc#page3.tif	

OP \$40.00 13024689

501546949

PATENT
REEL: 026353 FRAME: 0900

ASSIGNMENT

WHEREAS, I, Nicholas V. Perricone, have invented one or more inventions described in the patent applications and Letters Patent of the United States shown in Schedule A; and

WHEREAS, Transdermal Biotechnology, Inc. (hereinafter "ASSIGNEE"), a corporation organized and existing under the laws of the state of Connecticut, and having a usual place of business at 639 Research Parkway, Meriden, CT 06450, desires to acquire an interest therein, in accordance with agreements duly entered into with me;

NOW, THEREFORE, for and in consideration of said agreements and of other good and valuable consideration, the receipt of which is hereby acknowledged, I have sold, assigned and transferred and do hereby sell, assign and transfer unto ASSIGNEE, its successors, assigns, and legal representatives, my entire right, title and interest in and throughout the United States of America, its territories and all foreign countries, in and to the invention(s) described in said patent applications and Letters Patent, together with my entire right, title and interest in and to said patent applications and Letters Patent or patent application that may claim priority thereto under United States law or international convention, including but not limited to non-provisionals, continuations, divisionals, designs, reissues, reexaminations, extensions, and substitutions of said Letters Patent, and any right, title and interest I may have in provisional applications to which said patent applications and Letters Patent claims priority and such Letters Patent that may issue thereon, said invention(s), patent applications and Letters Patent to be held and enjoyed by ASSIGNEE for its own use and behalf and for its successors, assigns and legal representatives, to the full end of the term for which said Letters Patent may be granted as fully and entirely as the same would have been held by me had this assignment and sale not been made; I hereby convey all of my rights arising under or pursuant to any and all United States laws and international agreements, treaties or laws relating to the protection of industrial property by filing any such applications for Letters Patent, including but not limited to any cause(s) of action and damages accruing prior to this assignment. I hereby acknowledge that this assignment, being of my entire right, title and interest in and to said invention(s), carries with it the right in ASSIGNEE to apply for and obtain from competent authorities in all countries of the world any and all Letters Patent by attorneys and agents of ASSIGNEE's selection and the right to procure the grant of all Letters Patent to ASSIGNEE in its own name as assignee of my entire right, title and interest therein;

AND, I hereby further agree for myself, my executors, and administrators to execute upon request any other lawful documents and likewise to perform any other lawful acts that may be deemed necessary to secure fully the aforesaid invention(s) to ASSIGNEE, its successors, assigns, and legal representatives, but at its or their expense and charges, including the execution of non-provisional, continuation, divisional, design, reissue, reexamination, substitution, or corresponding foreign or international patent applications;

AND, I hereby further agree to provide statements or testimony in any interference or other proceeding in which said invention(s) or any patent application or Letters Patent directed thereto may be involved;

AND, I hereby authorize ASSIGNEE or its attorneys or agents to insert the correct serial number and filing date into this assignment, if none is indicated on the date of my execution of this assignment;

AND, I hereby authorize and request the Director of the United States Patent and Trademark Office and the empowered officials of all other governments to issue such Letters Patent as shall be granted upon said application, or applications based thereon, to ASSIGNEE, its successors, assigns, or legal representatives.

IN TESTIMONY WHEREOF, I have hereunto set my hand and affixed my seal on the date set forth below.

Inventor:

Nicholas V. Perricone
Nicholas V. Perricone

State/Commonwealth of Connecticut)
County of New Haven) ss Notary

On this 27 day of March, 2007, before me, the undersigned Notary Public, the above-named [INVENTOR'S NAME], personally appeared and proved to me through satisfactory evidence of identification, to be the person whose name is signed above, and who swore or affirmed to me that the contents of the document are truthful and accurate to the best of his/her knowledge and belief.

Carol M. Reed
Signature of Notary

(Seal)

My Commission Expires: 7-31-07

Carol M. Reed
NOTARY PUBLIC
My Commission Expires July 31, 2007

Schedule A

Title	Country	Appl. Serial No.	Patent No.	Date Filed
Topical Administration Of Insulin; Topical Drug Delivery	UNITED STATES	60/437,279		12/31/2002
Stabilized Insulin Compositions	UNITED STATES	10/750,390		12/31/2003
Topical Drug Delivery Using Phosphatidylcholine	AUSTRALIA	2003303517		12/31/2003
Topical Drug Delivery Using Phosphatidylcholine	BRAZIL	PI0317876-5		12/31/2003
Topical Drug Delivery Using Phosphatidylcholine	CANADA	2511849		12/31/2003
Topical Drug Delivery Using Phosphatidylcholine	CHINA	200380108020.0		12/31/2003
Topical Drug Delivery Using Phosphatidylcholine	EPO	3815011.6		12/31/2003
Topical Drug Delivery Using Phosphatidylcholine	HONG KONG	6101457.8		2/2/2006
Topical Drug Delivery Using Phosphatidylcholine	HONG KONG	6103997.1		3/31/2006
Stable Topical Drug Delivery Compositions	ISRAEL	169169		12/31/2003
Stable Topical Drug Delivery Compositions	JAPAN	2004-565850		12/31/2003
Stable Topical Drug Delivery Compositions	SOUTH KOREA	2005-7012203		12/31/2003
Stable Topical Drug Delivery Compositions	MEXICO	PA/a/2005/007023		12/31/2003
Stable Topical Drug Delivery Compositions	WIPO	PCT/US2003/041671		12/31/2003
Stable Topical Drug Delivery Compositions	SOUTH AFRICA	2005/05191	2005/05191	12/31/2003
Stable Topical Drug Delivery Compositions	UNITED STATES	10/749,914		12/31/2003
Stable Topical Drug Delivery Compositions	UNITED STATES	11/344,442		1/31/2006
Stable Topical Drug Delivery Compositions	UNITED STATES	11/506,137		8/17/2006
Stable Topical Drug Delivery Compositions	UNITED STATES	60/384,597		5/31/2002
Methods For Formulating Stabilized Insulin Compositions	UNITED STATES	10/448,632		5/30/2003
Stable Topical Drug Delivery Compositions	AUSTRALIA	2003231943	2003231943	11/30/2004
Stable Topical Drug Delivery Compositions	CANADA	2487305		6/2/2003
Topical Drug Delivery Using Phosphatidylcholine	CHINA	3818027.8		6/2/2003
Topical Drug Delivery Using Phosphatidylcholine	EPO	3756329.3		6/2/2003
Method For Delivering Stable Topical Drug Compositions	HONG KONG	6103057.8		3/9/2006
Stable Topical Drug Delivery Compositions	ISRAEL	166480		6/2/2003
Topical Drug Delivery Using Phosphatidylcholine	JAPAN	2004-508835		6/2/2003
Stable Topical Drug Delivery Compositions	WIPO	PCT/US2003/017220		6/2/2003
Stable Topical Drug Delivery Compositions	UNITED STATES	11/334,206		1/18/2006

{B0616342; 1}